Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer

OncoTargets and Therapy
Yoshihito OhharaToshiharu Yamaguchi

Abstract

A previous pivotal Phase III study (NO16966) demonstrated the benefit of the addition of bevacizumab (BV) to oxaliplatin-based regimens in metastatic colorectal cancer (MCRC). Our study evaluated the safety and efficacy of three oxaliplatin-based chemotherapy regimens (FOLFOX4 [intravenous twice-bolus and twice-infusional 5-fluorouracil/folinic acid plus oxaliplatin], mFOLFOX6 [intravenous once-bolus and once-infusional 5-fluorouracil/folinic acid plus oxaliplatin], and XELOX [capecitabine plus oxaliplatin]) plus BV in the first-line treatment of MCRC patients. Patients with MCRC who started treatment between June 2007 and September 2010 were evaluated in this retrospective cohort study. We also evaluated early objective tumor response (EOTR) within 12 weeks, which was defined as a relative change of ≥30% in the sum of the longest diameters of target lesions when compared with baseline. The primary study endpoints were progression-free survival (PFS) and response rate. A total of 185 patients received the following chemotherapy: FOLFOX4 + BV (FF4 arm, n=85), mFOLFOX6 + BV (FF6 arm, n=40), and XELOX + BV (XELOX arm, n=60). The overall response rates were 61.2%, 72.5%, and 75.0% (95% confidence interval: 50.6%-71.8%, 58.0%-87.0%,...Continue Reading

Citations

Jul 15, 2015·Expert Opinion on Therapeutic Patents·Esmeralda CarrilloJuan Antonio Marchal
Apr 17, 2021·Nature Reviews. Disease Primers·Diamantis I TsilimigrasTimothy M Pawlik

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Software Mentioned

SPSS

Related Concepts

Related Feeds

Bacterial Vaginosis

Bacterial vaginosis can increase the risk of sexually transmitted infections and in rare cases lead to pelvic inflammatory diseases. Discover the latest research on Bacterial Vaginosis here.